Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

M. Veronica Dioverti; David C. Gaston; C. Paul Morris; Carol Ann Huff; Tania Jain; Richard Jones; Viki Anders; Howard Lederman; Jacqueline Saunders; Heba H. Mostafa; Robin K. Avery

doi:10.1093/ofid/ofac064

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

M. Veronica Dioverti, David C. Gaston, C. Paul Morris, Carol Ann Huff, Tania Jain, Richard Jones, Viki Anders, Howard Lederman, Jacqueline Saunders, Heba H. Mostafa, Robin K. Avery

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

Original language	English (US)
Article number	ofac064
Journal	Open Forum Infectious Diseases
Volume	9
Issue number	6
DOIs	https://doi.org/10.1093/ofid/ofac064
State	Published - Jun 1 2022

Keywords

B-cell-depleted
monoclonal antibodies
prolonged SARS-CoV-2

ASJC Scopus subject areas

Infectious Diseases
Oncology

Access to Document

10.1093/ofid/ofac064

Cite this

Dioverti, M. V., Gaston, D. C., Morris, C. P., Huff, C. A., Jain, T., Jones, R., Anders, V., Lederman, H., Saunders, J., Mostafa, H. H., & Avery, R. K. (2022). Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients. Open Forum Infectious Diseases, 9(6), Article ofac064. https://doi.org/10.1093/ofid/ofac064

@article{f1e3fa739a4b491facfb5a2bcef46409,

title = "Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients",

abstract = "Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.",

keywords = "B-cell-depleted, monoclonal antibodies, prolonged SARS-CoV-2",

author = "Dioverti, {M. Veronica} and Gaston, {David C.} and Morris, {C. Paul} and Huff, {Carol Ann} and Tania Jain and Richard Jones and Viki Anders and Howard Lederman and Jacqueline Saunders and Mostafa, {Heba H.} and Avery, {Robin K.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = jun,

day = "1",

doi = "10.1093/ofid/ofac064",

language = "English (US)",

volume = "9",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

AU - Dioverti, M. Veronica

AU - Gaston, David C.

AU - Morris, C. Paul

AU - Huff, Carol Ann

AU - Jain, Tania

AU - Jones, Richard

AU - Anders, Viki

AU - Lederman, Howard

AU - Saunders, Jacqueline

AU - Mostafa, Heba H.

AU - Avery, Robin K.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

AB - Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

KW - B-cell-depleted

KW - monoclonal antibodies

KW - prolonged SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85132982575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132982575&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofac064

DO - 10.1093/ofid/ofac064

M3 - Article

C2 - 35663288

AN - SCOPUS:85132982575

SN - 2328-8957

VL - 9

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 6

M1 - ofac064

ER -

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this